Inhibition of human La protein by RNA interference downregulates hepatitis B virus mRNA in 2.2.15 cells

Qin Ni, Zhi Chen, Hang-Ping Yao, Zheng-Gang Yang, Ke-Zhou Liu, Ling-Ling Wu

AIM: To investigate the role of human La protein in HBV mRNA expression.

METHODS: Three human La protein (hLa) specific siRNA expression cassettes (SECs) containing U6+1 snRNA promoter and to deplete the hLa protein by RNA interference downregulates hepatitis B virus mRNA in 2.2.15 cells. Directly transfected into HepG2 cells, resulting in decreased by 8- and 66-fold in U6+1-hLa833 transfected cells compared to control. Accordingly, HBsAg and HBeAg secretions were decreased partly posttransfection with SECs.

RESULTS: SEC products containing U6+1 snRNA promoter, and 3 sites of hLa mRNA specific siRNA were obtained successfully by one-step overlapping extension PCR. After transfection with SECs into HepG2 cells, resulting in inhibition of La protein expression in both mRNA and protein levels, among which U6+1-hLa833 was the most efficient, which reduced 18.6-fold mRNA and 89% protein level respectively. In 2.2.15 cells, U6+1-hLa833 was also efficient on inhibition of hLa expression. Furthermore, semi-quantitative RT-PCR showed that HBs and HBe mRNA levels were significantly decreased by 8- and 66-fold in U6+1-hLa833 transfected cells compared to control. Accordingly, HBsAg and HBeAg secretions were decreased partly posttransfection with SECs.

CONCLUSION: PCR-based SECs can be used to mediate RNAi in mammalian cells and provide a novel approach to study the function of La protein. The inhibition of La protein expression can result in a significant decrease of HBV mRNA, which implies that the hLa protein is also involved in HBV RNA metabolism as one of the HBV RNA-stabilizing factors in human cells.

INTRODUCTION

Human La protein is a 47-kD phosphoprotein predominantly localized in nuclei. La protein is a member of RNA-binding proteins containing RNA recognition motifs (RRM) and interacts with RNA polymerase III transcripts such as pre-tRNA by binding to a small stretch of uridines at the 3’-end common to these transcripts and might be necessary for proper processing of these precursors[8-12] . In addition, La protein is known to interact with a variety of viral RNAs for stabilizing various RNAs[13-17] , and is required for viral internal ribosomal entry site (IRES) -mediated translation[10-12] . La protein has been identified as a host factor potentially involved in the cytokine-induced post-transcriptional down-regulation of hepatitis B virus (HBV) RNA[13] . A strong correlation between cytokine-mediated disappearance of HBV RNA and cytokine-induced processing of full-length mouse La protein (mLa) was observed. The mLa binding site was mapped to a predicted stem-loop structure within a region located at the 5’-end of the post-transcriptional regulatory element of HBV shared by all HBV RNAs[5,6] . In addition, HBV RNA was accessible to endoribonucleolytic cleavage near this mLa binding site and HBV RNA substrates were more efficiently cleaved after induction of mLa processing[7] . All these findings indicate that La protein might be an HBV RNA-stabilizing factor. Determination of the high affinity interaction between human La protein (hLa) and HBV RNA in vitro[14] , which is similar to that of mLa-HBV RNA interaction, implied that hLa might be involved in HBV RNA metabolism. But the role of human La protein (hLa) in HBV RNA metabolism in vivo is still unknown at present.

RNA interference (RNAi) is a process of sequence-specific post-transcriptional gene silencing via double-stranded RNA (dsRNA) present in plants and invertebrates[13] . With the increasing findings that 21-23 nt RNA duplexes known as small interfering RNA (siRNA) can also specifically and effectively knock down target gene expression in mammalian cells but short enough to evade host response[16,17] , RNAi has been promptly developed into a powerful tool for studying protein function.

In this report, we utilized PCR-based siRNA strategy[17-19] to obtain several hLa-specific siRNA expression cassettes (SECs) containing U6+1 snRNA promoter and to deplete the hLa expression by transfection with SECs into human cells. In a stable HBV-producing cell line 2.2.15 cells[20] , the inhibition of hLa expression resulted in a significant decrease of HBV mRNA and partly reduction of HBV antigen secretion. This result suggests that human La protein also plays an important role in HBV expression.

MATERIALS AND METHODS

Reagents and materials

Pyrobest DNA polymerase was obtained from Takara Biotech (Japan). TaqPlus DNA polymerase was purchased from Dingguo (China). QIAquick PCR purification kit was obtained from Qiagen (Germany). M-MuLV reverse transcriptase was obtained from MBI fermentas (Lithuania). G418 was from...
Clontech (USA). Fetal calf serum was from Hyclone (USA). Trizol reagent and Lipofectamine 2000 were obtained from Invitrogen Lifetechology (USA). Mouse monoclonal antibody against human La protein was purchased from BD Biosciences (USA). Rabbit polyclonal antibody against actin was from Wuhan Boster Biological Technology (China). Donkey anti-mouse and goat anti-rabbit horseradish peroxidase (HRP)-IgG were from SantaCruz (USA). Re-Blot Plus Western blot recycling kit was obtained from Chemicon (USA). SuperSignal west dura extended duration substrate ECL kit and CL-Xposure film were obtained from Pierce Biotech (USA). AxSYM and detective kits of HBsAg and HBeAg were purchased from ABBOTT (USA). Polyvinylidene difluoro (PVDF) membranes were obtained from Millipore (USA). All PCR primers were synthesized by Shanghai Sangon Biological Company (China).

Plasmids and cell lines
Plasmid pAVU6+27 was a gift of Dr. Paul D. Good (Engelke Laboratory, Department of Biological Chemistry). Plasmid pcDNA3.1 was obtained from Clontech (USA). HepG2, a human hepatoblastoma cell line, and 2.2.15 cells derived from HepG2 cells and stably transfected with HBV DNA[20] were maintained in our laboratory.

Selection of siRNA and shRNA design
Target sites of siRNA were determined by using on-line tool from Ambion Company. Three sites for hLa located downstream of the start codon were selected, their sequences are as follows: coding region 347-357 (5'-AAGGCTCTCC AACTGATGC AA-3') for hLa347, 833-843 (5'-AAGCCAAAG GAACCAT TGGGTA-3') for hLa833, 911-921 (5'-AAGTACTAGAA GAGAGGTGG-3') for hLa911. 5'-AAGGGCGAGG TTCAAGAGA-3' as 9-nt loop, all short hairpin RNAs (shRNA) were designed according to the structure of siRNA coding region 347-357 (5'-AAGGCTTCCC AACTGATGC). Information of primers is shown in Table 1. The PCR primer and Mu-MLV reverse transcriptase, and 0.5 µg of total RNA were reverse transcribed to cDNA using oligo (dT) 18 as primer and Mu-MLV reverse transcriptase, and 0.5 µL of the cDNA template was separately used to amplify different mRNA. Information of primers is shown in Table 1. The PCR conditions for different target were as follows. A total of 28 cycles for GAPDH were performed, each at 94 °C for 30 s, at 60 °C for 30 s, and at 72 °C for 30 s. A total of 26 cycles for hLa were performed, each at 94 °C for 30 s, at 58 °C for 30 s, and at 72 °C for 30 s. A total of 26 cycles for HBs were performed, each at 94 °C for 30 s, at 56 °C for 30 s, and at 72 °C for 30 s. A total of 30 cycles for HBe were performed, each at 94 °C for 30 s, at 46 °C for 30 s, and at 72 °C for 45 s. After electrophoresis and scanning, all PCR product bands were analyzed by using the software Gel Pro analyzer32 and relative mRNA expression was estimated by normalization with GAPDH.

**Table 1** PCR primers for amplification

| Primer | GenBank accession No | Sequence of primer pair |
|--------|----------------------|------------------------|
| GAPDH  | BC023632 (26-260)    | Sense 5'-TGGGGAAGGTGAAGGTCGGA-3' |
| hLa    | BC001289 (871-1313)  | Antisense 5'-GGGATCTCCTGCTGCTCGAAAGA-3' |
| HBs    | U95551 (232-681)     | Sense 5'-GGGATCTCCTGCTGCTCGAAAGA-3' |
| HBe    | U95551 (1816-2452)   | Antisense 5'-TAAACTGACGCAAGGAAACG-3' |

**Figure 1** Schematic representation of one-step overlapping extension PCR strategy used to yield SECs.

**Cell culture and cotransfection**
HepG2 cells were maintained in Dulbecco’ s modified Eagle’ s minimal essential medium (DMEM) supplemented with 100 mL/L FCS, streptomycin (100 µg/mL) and penicillin (100 IU/mL) at 37 °C in a humidified atmosphere containing 5% CO2. 2.2.15 cells were grown in DMEM with 100 mL/L FCS, 400 µg/mL G418. HepG2 and 2.2.15 cells were seeded into 24-well plates 24 h or 48 h prior to transfection. HepG2 cells at 50% confluence and 2.2.15 cells at 70% were prepared for transfection. For all co-transfections, a total of 0.05 µg pcDNA3.1+ (used as carrier DNA) and 0.2 µg SEC was delivered using Lipofectamine 2000 according to the manufacturer’ s instructions. HepG2 cells were harvested for analysis of La mRNA and protein expression. 2.2.15 cells and supernatants were harvested for detection of HBV mRNA and antigen.

**RNA extraction and semi-quantitative RT-PCR analysis**
Total RNA was extracted from cells with Trizol reagent according to the manufacturer’ s instructions, 1.0 µg of total RNA was reverse transcribed to cDNA using oligo (dT) 18 as primer and Mu-MLV reverse transcriptase, and 0.5 µL of the cDNA template was separately used to amplify different mRNA. Information of primers is shown in Table 1. The PCR conditions for different target were as follows. A total of 28 cycles for GAPDH were performed, each at 94 °C for 30 s, at 60 °C for 30 s, and at 72 °C for 30 s. A total of 26 cycles for hLa were performed, each at 94 °C for 30 s, at 58 °C for 30 s, and at 72 °C for 30 s. A total of 26 cycles for HBs were performed, each at 94 °C for 30 s, at 56 °C for 30 s, and at 72 °C for 30 s. A total of 30 cycles for HBe were performed, each at 94 °C for 30 s, at 46 °C for 30 s, and at 72 °C for 45 s. After electrophoresis and scanning, all PCR product bands were analyzed by using the software Gel Pro analyzer32 and relative mRNA expression was estimated by normalization with GAPDH.
**Results**

**RNAi inhibited hLa protein expression in cultured HepG2 cells**

To determine whether siRNA specific to the hLa gene sequence could inhibit hLa expression, we screened the activity of three sites of hLa-specific siRNA by semi-quantitative RT-PCR of hLa mRNA in HepG2 cells 36 h posttransfection with SECs. Two of them, SEC U6+1-hLa347 and U6+1-hLa833 significantly decreased hLa mRNA levels by about 8.8- and 17.6-fold respectively as compared with the control (Figure 2A). However, SEC U6+1-hLa911 only slightly affected hLa mRNA expression (1.3-fold reduction). No significant inhibition of hLa mRNA expression was detected in cells transfected with SEC U6+1-EGFP10 (Figure 2A). Furthermore, we performed Western blot analysis to verify the inhibitory effects on hLa protein expression levels 72 h posttransfection with SEC U6+1-hLa347 and U6+1-hLa833. As shown in Figure 2B, hLa protein expression almost could not be detected in cells transfected with U6+1-hLa833. After normalized to actin, the level of hLa protein expression was reduced to approximately 11% and 95% of the control cells for U6+1-hLa833 and U6+1-hLa347, respectively, and no reduction was found for U6+1-EGFP10. These data demonstrated that SEC-mediated RNAi could effectively inhibit hLa mRNA expression in cultured 2.2.15 cells, but the inhibitory effects could last only for a short time.

**Inhibition of hLa expression led to reduction of HBV mRNA levels in cultured 2.2.15 cells**

In order to investigate the relationship between hLa mRNA and HBV RNA expression, using the same samples, the levels of HBs and HBe mRNA expression in SEC-transfected 2.2.15 cells were detected by semi-quantitative RT-PCR. The HBs mRNA levels were also decreased about 8- and 2.8-fold in the first 2 d posttransfection, which were associated with a parallel reduction of hLa mRNA levels (Figure 3B). Moreover, HBe mRNA decreased dramatically, and almost could not be detected in the first 2 d and the inhibitory effect could last for at least 9 d (Figure 3C). In contrast, no significant changes in HBs and HBe mRNA levels were observed in cells posttransfection with SEC U6+1-EGFP10 (Figures 3B and 3C). These results demonstrated that RNAi against hLa could lead to reduction of HBV mRNA levels in 2.2.15 cells.

**Inhibition of hLa expression affected HBsAg and HBeAg secretion in 2.2.15 cells**

If the inhibition of hLa expression could affect HBs and HBe secretion, we further assessed the inhibitory effects of hLa RNAi on HBsAg and HBeAg secretion in 2.2.15 cells. Supernatants of 2.2.15 cells were harvested on days 1, 2, 3, 6 and 9 posttransfection respectively in same wells. Each experiment well was performed in triplicate. A microparticle enzyme immunoassay (MEIA) method was applied for the detection of HBsAg and HBeAg according to the kit’s instructions. Sample with S/N values great than or equal to 2.0 for HBsAg, and S/CO values great than or equal to 2.1 for HBeAg were considered reactive as described previously [21].
mRNA expressions in 2.2.15 cells, HBsAg and HBeAg secretion would be affected accordingly. Supernatant of SEC-transfected and control cells was harvested in the same period of posttransfection, HBsAg and HBeAg concentrations in the culture media were measured by MEIA method. Figure 4A shows that transfection with SEC U6+1-hLa833 inhibited the secretion of HBsAg in 2.2.15 cells from days 3 to 9 posttransfection in comparison with that of SEC U6+1-EGFP10 (P<0.05). The maximal inhibitory effect on day 6 posttransfection was 40%, and returned to 26% on d 9. HBeAg secretion was inhibited 38% on d 3 posttransfection with SEC U6+1-hLa833 and remained 46% and 51% on d 6 and 9 respectively (Figure 4B). There was a significant difference (P<0.05) in HBeAg secretion between SEC U6+1-hLa833- and U6+1-EGFP10-transfected cells on d 3, 6 and 9 posttransfection.

**DISCUSSION**

Results showed here from studies in 2.2.15 cells using siRNA against human La protein revealed a significant reduction in hLa expression, that resulted in HBV mRNA level simultaneously, especially the expression of HBe mRNA, which was markedly decreased in the first 3 d and maintained at a lower level on the 9th d after inhibition of hLa expression. Following HBV mRNA reduction, HBsAg and HBeAg secretions were decreased accordingly though reduction of HBV antigen was less significant than that of corresponding mRNA. The relevance of RNAi-mediated knockdown of hLa towards reduction of HBV mRNA level suggested that human La protein might also be involved in HBV RNA metabolism. Based on the previous findings of the high affinity interaction between human La protein (hLa) and HBV RNA in *vitro*,[14] and mouse La protein might be an HBV RNA-stabilizing factor in HBV-transgenic mouse model[15,17]. Our results invited a presumption that La protein might also play a role in stabilizing HBV RNA in human cells. However, HBsAg and HBeAg secretions could be affected slightly by hLa expression level, indicating that La protein is not a unique factor, and additional factors could contribute to viral RNA stability or HBV expression regulation. Therefore, using only hLa as targets for a novel antiviral strategy[14] would not be practical. Experiments to investigate the role of other RNA-binding proteins in HBV RNA metabolism might gain better insights into this problem.

We also observed that downregulation of HBe seemed more significant than HBs, implying more abundant HBs mRNA could generate HBsAg than HBe in 2.2.15 cells, which was in accord with the redundant HBsAg expression and secretion from patients with HBV infection. So HBs might be poorly susceptible to interfering factors. In addition, the feature of overlapping reading frames made entire 2.1-kb mRNA sequence encode HBs that was contained in 3.5-kb mRNA sequence encoding HBe[22,23]. In fact, HBs mRNA level detected by RT-PCR in our experiments represented the total transcript level containing HBs and HBe. Therefore, instead of RT-PCR, Northern blot analysis should reflect the truth of all HBV transcripts in more detail.

As to siRNA application in RNAi technology, besides chemically synthesized 21-nt siRNA duplexes,[16] some approaches could generate siRNA for various needs, such as *in vitro* transcribed siRNA,[24,25] plasmid DNA expression vector-based siRNA,[26,27] viral vector-based siRNA,[28,29] and PCR-based siRNA expression cassette (SEC)[27,30] which was proved to be a rapid, facile and cheap approach for identification of optimal siRNA-targets. In this report, we attempted to simplify the commonly used two-step PCR into overlapping-extension one-step PCR reaction by using three primers: a long specific extension primer and two universal primers, and also successfully prepared SECS targeting three sites of hLa mRNA. After transfection with these SECS into HepG2 cells, SEC U6+1-hLa833 demonstrated that strong RNAi effect was promptly screened out as optimal SEC to be used for further study. As a 347-bp in length of SEC DNA, it is often difficult to transfect them into mammalian cells, but using plasmid as carrier DNA, the efficiency of transfection seemed to be improved significantly (data not shown). On the other hand, stability of SEC DNA in cells should be considered. Despite SECS were phosphorylated for enhancing resistance to nuclease in cells, but target mRNA level still returned to normal on day 3 posttransfection, which maintained RNAi effect not as long as reported in application of vector-based siRNA,[26] indicating that SEC strategy should be just adapted to transient gene silencing at present and the better modification strategies should be developed for its stability.

To our knowledge, this is the first report that describes the role of human La protein in HBV expression in cultured human cells. Elucidating the mechanism of human La protein affecting HBV expression and replication will allow a deeper understanding of the interaction between host factors and HBV during HBV infection and clearance, and will provide useful clues for controlling HBV infection.

**ACKNOWLEDGEMENTS**

We thank Dr. Paul D. Good (Engelke Laboratory) for supplying plasmid pAVU6+27. We also thank Dr. Jian-Er Wo, Dr. Yu Chen and Dr. Jun-Bin Shao for technological support, and Dr. Edward Zumbika for English revision of this paper.

**REFERENCES**

1. Chakshusmathi G, Kim SD, Robinson DA, Wolin SL. A La protein requirement for efficient pre-tRNA folding. EMBO J 2003;
virus RNA-binding proteins associated with cytokine-induced recognition of a predicted stem-loop in hepatitis B virus RNA.  

Heise T, Guidotti LG, Cavanaugh VJ, Chisari FV. Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice. J Virol 1999; 73: 474-481

Heise T, Guidotti LG, Chisari FV. Hepatitis B virus autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA. J Virol 1999; 73: 5767-5776

Heise T, Guidotti LG, Chisari FV. Characterization of nuclear RNAs that cleave hepatitis B virus RNA near the La protein binding site. J Virol 2001; 75: 6874-6883

Pudi R, Abhiman S, Srinivasa N, Das S. Hepatitis C virus internal ribosome entry site-mediated translation is stimulated by specific interaction of independent regions of human La autoantigen. J Biol Chem 2003; 278: 12231-12240

Ali N, Prujin GJ, Kenan DJ, Keene JD, Siddiqui A. Human La antigen is required for the hepatitis C virus internal ribosome entry site-mediated translation. J Biol Chem 2002; 275: 27531-27540

Cheung P, Zhang M, Yuan J, Chau D, Yanagawa B, McM anus B, Yang D. Specific interactions of HeLa cell proteins with Coxackievirus B3 RNA: La autoantigen binds differentially to multiple sites within the 5’ untranslated region. Virus Res 2002; 90: 23-36

Ray PS, Das S. La autoantigen is required for the internal ribosome entry site-mediated translation of Coxackievirus B3 RNA. Nucleic Acids Res 2002; 30: 4500-4508

De Nova-Ocampo M, Villegas-Sepulveda N, del Angel RM. Translation elongation factor-1alpha, La, and PTB interact with the 3’ untranslated region of dengue 4 virus RNA. Virology 2002; 295: 337-347

Tsui LV, Guidotti LG, Ishikawa T, Chisari FV. Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes. Proc Natl Acad Sci U S A 1999; 92: 12398-12402

Horke S, Reumann K, Rang A, Heise T. Molecular characterization of the human La protein/ hepatitis B virus RNA.B interaction in vitro. J Biol Chem 2002; 277: 34949-34958

Hannon GJ. RNA interference. Nature 2002; 418: 244-251

Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498

Castanotto D, Li H, Rossi JJ. Functional siRNA expression from transfected PCR products. RNA 2002; 8: 1454-1460

Gou D, Jin N, Liu L. Gene silencing in mammalian cells by PCR-based short hairpin RNA. F E B S Lett 2003; 548: 113-118

Zheng L, Liu J, Babalov S, Zhou D, Orth A, Ding S, Schultz PG. An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc Natl Acad Sci U S A 2004; 101: 135-140

Selis MA, Chen ML, Acis G. Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 1987; 84: 1005-1009

Chen Y, Wu W. Determination of low-level HBsAg in serum by microparticle enzyme immunoassay. Hepatobiliary Pancreat Dis Int 2002; 1: 262-264

Moolia N, Kew M, Arbuthnot P. Regulatory elements of hepatitis B virus transcription. J Viral Hepat 2002; 9: 323-331

Seeger C, Mason WS. Hepatitis B Virus Biology. Microbiol Mol Biol Rev 2000; 64: 51-68

Anderson J, Banerjea A, Planelles V, Akkina R. Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Res Hum Retroviruses 2003; 19: 699-706

Mayers JW, Jones JT, Meyer T, Ferrell JE Jr. Recombinant Dicer efficiently converts large dsRNAs into siRNAs suitable for gene silencing. Nat Biotechnol 2003; 21: 324-328

Paul CP, Good PD, Winer I, Engelke DR. Effective expression of small interfering RNA in human cells. Nat Biotechnol 2002; 20: 505-508

Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553

Liu CM, Liu DP, Dong WJ, Liang CC. Retrovirus vector-mediated stable gene silencing in human cell. Biochem Biophys Res Commun 2004; 313: 716-720

Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinjaj, Rooney DL, I rhg MM, McM anus MT, Gertler FB, Scott ML, Van Parjis L. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003; 33: 401-406

Zhao LJ, Jian H, Zhu H. Specific gene inhibition by adenovirus-mediated expression of small interfering RNA. Gene 2003; 316: 137-141

Edited by Wang XL. Proofread by Chen WW and Xu FM